Lertec

Enalapril maleate and lercanidipine hydrochloride, the active ingredients in Lertec, are an ACE inhibitor and a calcium‑channel blocker presented as oral tablets for systemic use. The combination is indicated for the management of elevated blood pressure in adult patients. GNH USA supplies Lertec as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lertec acts on the renin‑angiotensin system and vascular smooth‑muscle calcium channels to lower blood pressure in hypertensive patients.

Essential hypertension: provides additive blood‑pressure reduction for patients with primary high blood pressure. Secondary hypertension: assists in controlling blood pressure when the underlying cause is identifiable. General high blood pressure: helps achieve target blood‑pressure goals in adults with elevated readings.

Lertec may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Cough: dry, persistent throat irritation. - Dizziness or light‑headedness, especially on standing. - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Flushing: transient warmth and redness. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Angio‑edema: rapid swelling of lips, tongue, or airway. - Severe hypotension: marked drop in blood pressure causing fainting. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Hyperkalemia: elevated potassium levels, potentially causing cardiac issues. - Renal impairment: worsening kidney function, especially in patients with pre‑existing disease. - Myocardial infarction: rare reports of heart attack in susceptible individuals.

Before initiating Lertec, consider patient‑specific factors and monitor for potential risks. - Renal function: assess baseline creatinine and adjust if impairment exists. - Electrolytes: monitor potassium levels, especially if combined with potassium‑sparing agents. - Pregnancy: avoid use unless clearly needed; discuss risks with a healthcare professional. - Concomitant antihypertensives: watch for additive blood‑pressure lowering effects. - Elderly patients: start at lower dose and monitor for orthostatic symptoms. Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and direct sunlight.

Lertec can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Aliskiren: combined use may cause excessive hypotension and renal dysfunction. - Lithium: increased lithium levels leading to toxicity. - Potassium‑sparing diuretics or supplements: risk of severe hyperkalemia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - Other ACE inhibitors or ARBs: additive risk of hypotension and renal impairment. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase lercanidipine plasma concentrations. - Diuretics: may enhance orthostatic hypotension, especially at therapy initiation.